Plain-English translation of NCT05526144 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether levothyroxine (a thyroid hormone medication) given at low doses can improve fatty liver disease, a serious condition where fat builds up in the liver and causes damage. Researchers believe this medication may help the liver burn fat more effectively, potentially reducing scarring and improving overall liver health. The study will compare people who take the medication to those who take a placebo (inactive pill) over one year.
Fatty liver disease is becoming increasingly common, especially among veterans, and can progress to cirrhosis and liver cancer. Currently, doctors can only recommend lifestyle changes like diet and exercise, which often don't work well enough. This trial explores whether this medication could offer a new treatment option for people with confirmed fatty liver disease.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the thyroid hormone medication or a placebo pill once daily for 52 weeks (one year). You'll need to have a liver biopsy before starting (if you haven't had one already) to confirm your diagnosis. During the study, you'll have regular clinic visits to check your health, blood work, and how well the medication is working, with your dose adjusted as needed to keep your thyroid function normal.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States